BA.3.2 is a heavily mutated subvariant of the Omicron lineage of SARS-CoV-2. It is a descendant of the earlier BA.3 variant, which had not circulated widely since the beginning of 2022. First identified in a sample collected in South Africa on November 22, 2024, the variant was later designated as a Variant Under Monitoring (VUM) by global health authorities in December 2025.Genetic Characteristics and Mutations The variant is characterized by a staggering number of genetic changes, carrying approximately 70 to 75 mutations in its spike protein relative to the original virus strain and recent dominant lineages. A large majority of these mutations are located in the Receptor Binding Domain (RBD) and the N-Terminal Domain (NTD), which are critical for the virus's ability to enter human cells and evade immune detection.BA.3.2 has diversified into two primary sublineages: BA.3.2.1 and BA.3.2.2. The BA.3.2.1 lineage includes mutations like H681R, which may enhance spike protein activation and viral entry, while BA.3.2.2—the more dominant subvariant in some regions—features a unique mutation that creates a new sequon in the spike protein.The "Cicada" Nickname Researchers nicknamed the variant "Cicada". This name was chosen because the variant’s trajectory resembles the insect's life cycle; it appeared to spend a long period circulating "underground" at low levelsbefore suddenly emerging and spreading on the global stage.Global and Domestic Spread Although it was first detected in late 2024, BA.3.2 began to spread more noticeably in late 2025. By early 2026, it had been reported in at least 23 countries, including Australia, Germany, Denmark, and the Netherlands. In the United States, the variant was first detected in June 2025 via traveler screening and has since been identified in clinical or wastewater samples across at least 25 states. Despite this widespread geographic presence, its global prevalence remained relatively low as of early 2026, typically representing less than 1% of total analyzed genetic sequences.Public Health Risk and Immunity The overall public health risk posed by BA.3.2 is currently assessed as low. There is no evidence suggesting that infection with this variant is associated with increased disease severity, higher rates of hospitalization, or more deaths compared to other circulating Omicron lineages. Laboratory studies also found that BA.3.2 may have reduced infectivity and lower lung cell entry compared to other dominant variants, which potentially limits its ability to become a globally dominant strain.However, BA.3.2 exhibits a marked antibody evasion profile. It is antigenically distinct from recent dominant variants, meaning it may more easily infect individuals who have immunity from previous infections or vaccinations. While currently approved vaccines are expected to continue providing protection against severe disease, laboratory studies suggest they may have reduced effectiveness in preventing infection from this specific lineage.Common Symptoms Symptoms associated with BA.3.2 are generally similar to those of other variants, though some researchers note specific patterns. Commonly reported signs include:

• Severe sore throat
• Cough, profound fatigue, and headache
• Congestion or a runny nose
• Fever or chills
• Intense night sweats, which is noted as a unique symptom associated with some Omicron subvariants

Other reported symptoms include gastrointestinal distress, muscle aches, and shortness of breath. Public health guidance in 2026 emphasizes a symptom-based approach to isolation, suggesting that individuals can end isolation once they have been fever-free for at least 24 hours without medication and other symptoms are significantly improving.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-world-between-us--6886561/support.